Search Results
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526 – 1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
półtrwania, ukierunkowany na DLL3, wykazuje wysoką siłę działania i wrażliwość w przedklinicznych modelach drobnokomórkowego raka płuca). Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy
More news about: Amgen
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
More news about: Amgen
Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
2026.8 Kawka L, et al. Fatigue in Systemic Lupus Erythematosus: An Update on Its Impact, Determinants and Therapeutic Management. J Clin Med. 2021 Sep 3;10(17):3996. doi: 10.3390/jcm10173996. PMID: 34501444; PMCID: PMC8432566.9 Guéry JC. Why Is Systemic Lupus Erythematosus
More news about: Johnson & Johnson
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
10.1038/s41584-023-01057-6.7 Meudec L, Nocturne G, Mariette X. Update on the Aetiopathogenesis of Sjögren Disease: From Interferon Signaling to Epithelial Dysfunction. J Clin Med. 2026 Mar 4;15(5):1945. doi: 10.3390/jcm150519458 Mayo Clinic. Sjogren's syndrome. Available at:
More news about: Johnson & Johnson
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology-302788575.htmlSOURCE
More news about: Karyopharm Therapeutics Inc.
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526-1537.Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin
More news about: Amgen
Jun 01, 2026, 04:19 ET Sobi to present new data on pegcetacoplan at ERA 2026
2. Servais A, et al. Kidney Int. 2012;82(4):454-464.3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.4. Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.5. Data on file using literature consensus.6. Fakhouri F, et al. N Engl J Med 2025;393:2210-2220CONTACT:
More news about: Swedish Orphan Biotrauma AB
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
doi:10.1007/s00405-020-06584-6 4 Nissi L, et al. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol. 2021;27:139-146. doi:10.1016/j.ctro.2021.01.0135 Dunn LA, Ho AL, Pfister DG. Head and neck cancer: a review.
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
real-world multi-country European study on patients with high-risk localised and locally advanced prostate cancer receiving radical treatment. J Clin Oncol. 2024;42:5024. DOI: 10.1200/JCO.2024.42.16_suppl.5026 Stattin P, et al. Population-based study of disease trajectory after
More news about: Johnson & Johnson
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
[email protected] J. J Clin Oncol 44, 2026 (suppl 17; abstr LBA2000).Lamba N, Wen PT, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro-Oncology.
More news about: GT Medical Technologies
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Tomasini P, Wang Y, Li Y, et al. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. J Clin Oncol. 2026;44(1):54-65. doi:10.1200/JCO-24-02835 3 Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected
More news about: Johnson & Johnson
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html9 Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. J Clin Oncol. 2018;36(15):1479–1487. https://pmc.ncbi.nlm.nih.gov/articles/PMC6119139/10
More news about: Johnson & Johnson
May 28, 2026, 08:25 ET Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
Abstract Number: e15162Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyCitation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)DOI: 10.1200/JCO.2026.44.16_suppl.e15162Clinical Trial Registration Number: CTRI/2024/08/072373
More news about: Lupin Pharmaceuticals, Inc.
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
https://onlinelibrary.wiley.com/doi/10.1002/ajh.27737. Accessed April 15, 2026.Pemmaraju, N. et al. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). J Clin Oncol 44, 861-873(2026). Available at
More news about: AbbVie
May 27, 2026, 10:21 ET Abbott erhält CE-Kennzeichnung für die weltweit erste duale Glukose-Keton-Sensortechnologie für Menschen mit Diabetes
sensorbasierter Glukosemessysteme für den persönlichen Gebrauch. Daten liegen vor. Abbott Diabetes Care Inc. 12. Dunn T et al. Diabetes Res Clin Pract. 2018 Mar;137:37-46.
More news about: Abbott
May 26, 2026, 10:50 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
al. A real-world study on the risk of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia. J Clin Lipidol. 2026 Apr 11:S1933-2874(26)00102-9. [3] Mach et al. 2019 European Heart Journal [4] Bashir B, Ferdousi
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 10:46 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
al. A real-world study on the risk of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia. J Clin Lipidol. 2026 Apr 11:S1933-2874(26)00102-9. [3] Mach et al. 2019 European Heart Journal [4] Bashir B, Ferdousi
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 02:27 ET Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
1. Wijeratne T et al. Eur J Neurol. 2019;26(11):e92-e93.2. Kim, BK et al. Cephalalgia 2013;33(13):1106-16.3. Kim BK et al. J Clin Neurol. 2022 ;18(5):571-5804. Steiner TJ, et al. J Headache Pain. 2018;19(1):175. Leonardi M, et al. J Headache Pain. 2005; 6(6):429–
More news about: H. Lundbeck A/S
May 25, 2026, 08:45 ET A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
2026.2. Davletov, K., et al. Prevalence of Familial Hypercholesterolemia and Its Association with Cardiovascular Risk in a Cross-Sectional Adult Population. J Clin Med. 2025 Nov 19;14(22):8213. doi: 10.3390/jcm14228213.3. Stark, B., et al. Global Prevalence of Coronary Artery Disease: An Update from
More news about: Eli Lilly and Company
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.htmlKato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML).
More news about: Rigel Pharmaceuticals, Inc.